Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
Status:
Completed
Trial end date:
2017-05-04
Target enrollment:
Participant gender:
Summary
Patients have a newly diagnosed brain tumor called a malignant glioma and participate in the
study to see if it is possible to increase the benefit of temozolomide when given after
radiation. A recent study showed that patients with newly diagnosed glioblastoma lived longer
when treated with both temozolomide and radiotherapy followed by 6 months of temozolomide
than patients treated with radiotherapy alone. Patients will receive standard low dose
temozolomide during radiation. After radiation, they will be randomized to receive either
more intense temozolomide or continuous low dose temozolomide.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Columbia University Dana-Farber Cancer Institute Schering-Plough